Filing Flows › Vivos Therapeutics (VVOS) › Q1 2026
Vivos Therapeutics (VVOS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 20, 2026
Vivos Therapeutics (VVOS) reported revenue of $5.1M for the first quarter 2026 (Q1 2026), +70% from a year earlier and +34% from the quarter before. Operating margin was -128.7%, net loss $7.8M (150.8% of revenue).
Vivos Therapeutics, Q1 2026: revenue $5.1M (+70% year over year), operating margin -128.7%, net loss $7.8M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.1M | +34% | +70% |
| Operating profit | −$6.6M | — | — |
| Net earnings | −$7.8M | — | — |
| Operating cash flow | −$6.0M | — | — |
What changed
Revenue was $5.1M in Q1 2026, up 70% year over year and up 34% from the previous quarter. Sleep Testing Services was the largest line at 45% of revenue. Sleep Testing Services added $2.0M year over year (up 611%), 93% of the total change. VIP declined 83%.
Gross margin was 59.5%, up 9.5 points from Q1 2025. Operating costs exceeded revenue by $6.6M, an operating margin of -128.7%. Operating expenses grew 78% against revenue growth of 70%. The fastest-growing cost line was Other operating costs (+156%). The quarter ended with a net loss of $7.8M, wider than the previous quarter's $6.9M loss. Minority interests bore $69K of it: to shareholders the quarter was a loss of $7.7M.
Operating cash flow was −$6.0M. Non-cash charges added back $454K of depreciation and amortization and $151K of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$6.0M.
Questions
What was Vivos Therapeutics' revenue in the first quarter 2026?
Vivos Therapeutics (VVOS) reported revenue of $5.1M for the first quarter 2026 (Q1 2026), +70% from a year earlier and +34% from the quarter before.
Was Vivos Therapeutics profitable in the first quarter 2026?
Operating loss was $6.6M (-128.7% of revenue) and net loss $7.8M.
Source: Vivos Therapeutics 10-Q on SEC EDGAR.